Pub Date : 2008-08-20DOI: 10.1185/146300908X292097
A. Hazen, F. Smith, K. Taylor, C. Rawcliffe, L. Medcalf, S. Keady
Aim: To assess patients' and parents' perspectives on the impact of infliximab treatment on daily life and the acceptability and feasibility of (infliximab or adalimumab) home treatment, in the light of the perceived value of hospital services. Methods: A descriptive qualitative study was conducted at University College Hospital London. Data were collected via 25 semi-structured interviews with patients (aged 14-19) from both gastroenterology and rheumatology specialties, prescribed infliximab, and their parents. Results: The majority of participants preferred to continue infliximab treatment at their current hospital, rather than be treated in their local hospital or at home. The main reasons were the specialised care in their current hospital, the continuity of care and hospital staff, resistance to the method of adalimumab administration and expected problems with compliance. Hospital services were highly valued and current infliximab treatment at the hospital was considered to have either no impact on family and school life, or to have improved it. Conclusion: Infliximab is an effective therapy for inflammatory bowel diseases and rheumatology conditions in young people, bringing either no negative impact on, or improvement of school and family life. In association with patients' and parents' positive appraisal for hospital services and their confidence in the clinical team, patients and parents do not express a preference for infliximab or adalimumab home treatment, despite current health policy aimed towards therapy closer to, or at, home.
{"title":"Paediatric infliximab therapy: Patients' and parents' perspectives on treatment options","authors":"A. Hazen, F. Smith, K. Taylor, C. Rawcliffe, L. Medcalf, S. Keady","doi":"10.1185/146300908X292097","DOIUrl":"https://doi.org/10.1185/146300908X292097","url":null,"abstract":"Aim: To assess patients' and parents' perspectives on the impact of infliximab treatment on daily life and the acceptability and feasibility of (infliximab or adalimumab) home treatment, in the light of the perceived value of hospital services. Methods: A descriptive qualitative study was conducted at University College Hospital London. Data were collected via 25 semi-structured interviews with patients (aged 14-19) from both gastroenterology and rheumatology specialties, prescribed infliximab, and their parents. Results: The majority of participants preferred to continue infliximab treatment at their current hospital, rather than be treated in their local hospital or at home. The main reasons were the specialised care in their current hospital, the continuity of care and hospital staff, resistance to the method of adalimumab administration and expected problems with compliance. Hospital services were highly valued and current infliximab treatment at the hospital was considered to have either no impact on family and school life, or to have improved it. Conclusion: Infliximab is an effective therapy for inflammatory bowel diseases and rheumatology conditions in young people, bringing either no negative impact on, or improvement of school and family life. In association with patients' and parents' positive appraisal for hospital services and their confidence in the clinical team, patients and parents do not express a preference for infliximab or adalimumab home treatment, despite current health policy aimed towards therapy closer to, or at, home.","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"177-181"},"PeriodicalIF":0.0,"publicationDate":"2008-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X254198
O. Dewit, R. Tiner
{"title":"Working with the pharmaceutical industry in relation to paediatric clinical trials. A British perspective","authors":"O. Dewit, R. Tiner","doi":"10.1185/146300908X254198","DOIUrl":"https://doi.org/10.1185/146300908X254198","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"140-144"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X254189
Matityahu Berkovitch, I. Choonara, É. Jacqz-Aigrain, B. Kalikstad, G. Pons, A. Rane, J. Anker, B. Overmeire
{"title":"Improving research and access to children's medicines worldwide","authors":"Matityahu Berkovitch, I. Choonara, É. Jacqz-Aigrain, B. Kalikstad, G. Pons, A. Rane, J. Anker, B. Overmeire","doi":"10.1185/146300908X254189","DOIUrl":"https://doi.org/10.1185/146300908X254189","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"138-139"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65624979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X292079
I. Choonara, A. Nunn
{"title":"A new partnership for drug therapy in children","authors":"I. Choonara, A. Nunn","doi":"10.1185/146300908X292079","DOIUrl":"https://doi.org/10.1185/146300908X292079","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"171-171"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X254224
H. Satish, H. Payne, F. Potter, A. Nunn, K. Brodbelt
{"title":"Delayed respiratory depression after accidental risperidone overdose","authors":"H. Satish, H. Payne, F. Potter, A. Nunn, K. Brodbelt","doi":"10.1185/146300908X254224","DOIUrl":"https://doi.org/10.1185/146300908X254224","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"154-156"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X292060
M. Odièvre, M. Benkerrou, M. Belloy, J. Elion
Sickle cell anaemia, the most prevalent genetic disease in the black population, is characterised by the polymerisation of the abnormal haemoglobin S, which leads to vascular occlusion and severe painful crisis. Hydroxyurea is the fi rst drug that has been shown to reduce the clinical severity of sickle cell anaemia in adults. Several trials have been carried out in more than 400 children in the last decade, using different therapeutic schedules. Enrolment was based on clinical vasoocclusive severity and few studies included children with cerebrovascular events. Hydroxyurea enhanced fetal haemoglobin expression in almost all the children, despite a large interindividual variability. Hydroxyurea signifi cantly reduces the number of vasoocclusive crises, hospitalisations, the frequency of the acute chest syndrome and the rate of transfusion. Long-term tolerance to hydroxyurea is good. However, clinical response does not correlate consistently with the degree and with the time of increment in fetal haemoglobin, suggesting that hydroxyurea may mediate some of its clinical benefi ts through other mechanisms such as the reduction of sickle erythrocytes – endothelial cells adherence and of the vasoconstrictive stimulus.
{"title":"Hydroxurea treatment in sickle cell children","authors":"M. Odièvre, M. Benkerrou, M. Belloy, J. Elion","doi":"10.1185/146300908X292060","DOIUrl":"https://doi.org/10.1185/146300908X292060","url":null,"abstract":"Sickle cell anaemia, the most prevalent genetic disease in the black population, is characterised by the polymerisation of the abnormal haemoglobin S, which leads to vascular occlusion and severe painful crisis. Hydroxyurea is the fi rst drug that has been shown to reduce the clinical severity of sickle cell anaemia in adults. Several trials have been carried out in more than 400 children in the last decade, using different therapeutic schedules. Enrolment was based on clinical vasoocclusive severity and few studies included children with cerebrovascular events. Hydroxyurea enhanced fetal haemoglobin expression in almost all the children, despite a large interindividual variability. Hydroxyurea signifi cantly reduces the number of vasoocclusive crises, hospitalisations, the frequency of the acute chest syndrome and the rate of transfusion. Long-term tolerance to hydroxyurea is good. However, clinical response does not correlate consistently with the degree and with the time of increment in fetal haemoglobin, suggesting that hydroxyurea may mediate some of its clinical benefi ts through other mechanisms such as the reduction of sickle erythrocytes – endothelial cells adherence and of the vasoconstrictive stimulus.","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"158-170"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X254215
S. Chu, J. Tan, J. Seabrook, M. Rieder
{"title":"Paediatric asthma severity score and length of stay in patients presenting to a paediatric emergency department","authors":"S. Chu, J. Tan, J. Seabrook, M. Rieder","doi":"10.1185/146300908X254215","DOIUrl":"https://doi.org/10.1185/146300908X254215","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"150-153"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1185/146300908X254206
Claire Skwierczynski, S. Conroy
{"title":"How long does it take to administer oral medicines to children","authors":"Claire Skwierczynski, S. Conroy","doi":"10.1185/146300908X254206","DOIUrl":"https://doi.org/10.1185/146300908X254206","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"145-149"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65625079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-11-01DOI: 10.1185/146300907X199939
R. Lim, B. García, M. Rieder, Priya Iyer, J. Seabrook
{"title":"Comparison of amethocaine gel versus 1% lidocaine infiltration on wound healing. A pilot study in animals","authors":"R. Lim, B. García, M. Rieder, Priya Iyer, J. Seabrook","doi":"10.1185/146300907X199939","DOIUrl":"https://doi.org/10.1185/146300907X199939","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"110-114"},"PeriodicalIF":0.0,"publicationDate":"2007-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65624872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-11-01DOI: 10.1185/146300908X254161
Meg Sears, C. Walker, R. Jagt
{"title":"Dioxins in children","authors":"Meg Sears, C. Walker, R. Jagt","doi":"10.1185/146300908X254161","DOIUrl":"https://doi.org/10.1185/146300908X254161","url":null,"abstract":"","PeriodicalId":87451,"journal":{"name":"Paediatric and perinatal drug therapy","volume":"8 1","pages":"134-134"},"PeriodicalIF":0.0,"publicationDate":"2007-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65624970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：